Lumos Diagnostics Holdings Ltd chief technology officer Dr. Sacha Dopheide talked with Proactive about the company’s follow-on contract with US-based Aptatek Biosciences Inc., focused on advancing the PheCheck™ in-home testing device for phenylketonuria (PKU).
The US$400,000 agreement marks a key milestone in the development pipeline, supporting a critical clinical study that will feed into the device’s FDA submission process.
#LumosDiagnostics #PheCheck #PKU #Phenylketonuria #PointOfCareTesting #Aptatek #MedicalDevices #FDAApproval #HealthcareInnovation #ClinicalTrials #ProactiveInvestors